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COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B
AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS
PATIENTS
Meletiche DM1, Kozma C2, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, 
USA, 3University of South Carolina, Columbia, SC, USA
OBJECTIVES: To compare medication adherence to interferon beta (IFNB)-1b and
IFNB-1a subcutaneous (SC) in patients with multiple sclerosis (MS). METHODS: This
was a retrospective analysis of patients with a diagnosis of MS in a national managed 
care database that had q1 outpatient DMD claim during the 7/1/2002 to 12/31/2005 
selection period. Eligible patients were continuously enrolled for 6 months before and 
24 months after their initial drug claim (index date) and were between 18 and 65 
years of age. Medication possession ratios (MPRs) were calculated as the percentage 
of ambulatory days during the 24-month post-index period from the date of ﬁ rst use 
of the index DMD. The primary analysis was logistic regression predicting likelihood 
of adherence (MPR q85%) by treatment group (IFNB-1b versus IFNB-1a SC), includ-
ing covariates of age, sex, and region of the country. RESULTS: A total of 530 MS 
patients (IFNB-1b, n  206, IFNB-1a SC, n  324) met the study criteria. Patients had 
a mean age of 43.6 years, 77.2% were women, 49.0% were located in the Midwest, 
and 94.2% had commercial insurance. Average 2-year MPRs were 57.9% and 63.7% 
(P  0.020) for IFNB-1b and IFNB-1a SC, respectively. The percentage of patients who 
were adherent (MPR q85%) was 39.3% for IFNB-1b vs 49.4% for IFNB-1a SC. A
logistic regression using categorical MPR as the dependent variable found that IFNB-
1a SC patients were signiﬁ cantly more likely to be adherent than IFNB-1b patients 
(OR  1.603, P  0.0110). Older age (in 10 year increments) was also a signiﬁ cant 
predictor of adherence (OR  1.301, P  0.0037). Sex and region of the country were 
not statistically signiﬁ cant. CONCLUSIONS: In this retrospective analysis, patients 
using IFNB-1a SC were more likely to be adherent with their DMD therapy over a 2-
year period than patients using IFNB-1b, while controlling for age, sex, and region of 
the country.
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PREVALENCE OF TREATMENT GAPS IN MULTIPLE SCLEROSIS 
PATIENTS RECEIVING DISEASE-MODIFYING DRUGS: FINDINGS FROM 
A NATIONAL MANAGED CARE DATABASE
Fincher C1, Kozma C2, Meletiche DM1, Dickson M3
1EMD Serono, Inc, Rockland, MA, USA, 2University of South Carolina, West Columbia, SC, 
USA, 3University of South Carolina, Columbia, SC, USA
OBJECTIVES: Although gaps in therapy with disease-modifying drugs (DMDs) may 
result in suboptimal treatment for patients with multiple sclerosis (MS), maintaining 
continuous therapy is a challenge in MS care. This study evaluated gaps in DMD
therapy in MS patients. METHODS: In this retrospective study, patients with a diag-
nosis of MS and q1 claim for a self-injectable DMD (index claim) between July 1, 
2000–December 31, 2005 were identiﬁ ed using a national managed care database.
Eligible patients (aged 18 to 65 years) were continuously enrolled for 6 months before
and 24 months after the index date, and had no nursing home claims. The analysis
excluded patients receiving natalizumab because most of the natalizumab claims did 
not contain the necessary days supply data. Maximum gap (MaxGap), which captures 
the maximum period of a given lapse in treatment per patient, was deﬁ ned as the
number of days between the lapsing of days supply of the prior prescription and fulﬁ ll-
ment of a new prescription over the 24-month observation period. MaxGap was also 
assessed between the ﬁ rst and last claim during the observation period. RESULTS: A 
total of 3101 MS patients (76.5% women) met the inclusion criteria for the study. 
The mean o standard deviation patient age was 44.0 o 9.4 years, and most (51.0%)
were from the Midwest. The results showed MaxGaps of q0 and 11 days in 20.5%
of patients, q11 and 31 days in 24.5%, q31 and 61 days in 11.3%, q61 and 
90 days in 6%, and q90 days in 37.7%. When examining the maximum gap between
the ﬁ rst and last prescription claim, 36% of patients had a MaxGap of q31 days.
CONCLUSIONS: Maintaining continuous DMD therapy remains a challenge for MS
patients. Over 24 months, more than one third of patients had a gap in therapy of 
q90 days.
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BURDEN OF MULTIPLE SCLEROSIS ON HEALTH-RELATED QUALITY OF
LIFE: BASELINE FINDINGS FROM AN OBSERVATIONAL STUDY
Jeffery D1, Kirzinger S2, Halper J3, Preblick R4, Jia Bi Y4, Bharmal M5
1Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2University of 
Louisville, Louisville, KY, USA, 3MS Center at HNH, Teaneck, NJ, USA, 4Bayer HealthCare
Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, 
USA, 5Quintiles, Inc, Falls Church, VA, USA
OBJECTIVES: To measure health-related quality of life (HRQoL) by SF-12 in multiple 
sclerosis (MS) patients and to compare the SF-12 component scores in MS patients
with available US national average scores (norm). METHODS: ROBUST is an 
ongoing multi-center prospective US observational study among MS patients, involv-
ing a series of questionnaires completed via a web tool. A battery of items in the
patient questionnaire is the SF-12 (Version 2). The ROBUST baseline SF-12 Physical 
Component Summary (PCS-12) and Mental Component Summary (MCS-12) scores 
were analyzed against US population norms. RESULTS: A total of 191 ROBUST
participants completed baseline HRQoL assessments and were included in this analy-
sis. The mean (SD) age was 40.6 (11.2) years and a majority were female (81.2%), 
white (86.9%), married (68.6%) and worked full- or part-time (61.2%). The MCS-12 
showed a gradual increase with the level of education. Among the ROBUST popula-
tion, the mean (SD) scores on PCS-12 [40.64 (11.18)] and MCS-12 [42.54 (11.44)] 
were signiﬁ cantly lower than the norm [PCS-12 norm: 49.63 (p  0.0001); MCS-12 
norm: 49.37 (p  0.0001)]. The PCS-12 [40.11 (11.17)] and MCS-12 [42.42 (11.44)]
scores for female MS patients and the PCS-12 [42.92 (11.08)] and MCS-12 [43.05
(11.55)] scores for male MS patients were also signiﬁ cantly lower than the respective
norms [all p  0.0001]. Similarly, SF-12 scores for MS patients by age groups [18–24 
years; 25–34 years; 35–44 years; 45–54 years; 55–64 years] were signiﬁ cantly lower
compared to norms for corresponding age groups [all p  0.001]. Among these age 
groups within the ROBUST population: PCS-12 scores were lower after 40 years 
compared to that in younger age group, while MCS-12 scores do not show this same 
change with age. CONCLUSIONS: SF-12 component scores were signiﬁ cantly reduced
in the ROBUST population compared to the available national average scores, sug-
gesting a lowering of general HRQoL in MS population.
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THE IMPACT OF LENNOX-GASTAUT SYNDROME (LGS) ON HEALTH
RELATED QUALITY OF LIFE – A CONCEPTUAL MODEL
Verdian L1, Gallop K2, Wild D2, Falconer S2
1Eisai Europe Limited, Hatﬁ eld, UK, 2Oxford Outcomes Ltd, Oxford, UK
OBJECTIVES: The onset of LGS during early childhood brings particular concerns
for the child with LGS and for the parents caring for the child with the condition.
LGS is a severe form of childhood epilepsy which is characterized by multiple seizures
and mental deﬁ ciency. This study was conducted to explore the impact of LGS on the 
HRQL of the parent and the child and to develop a conceptual model. METHODS:
Semi-structured interviews were conducted with 40 parents of children with LGS
in the US, UK, and Italy. Given the fact that it was not possible to interview the
children, parents were asked to provide a report on their perceptions of the HRQL 
of their child in addition to describing the impact on their own HRQL. Thematic
analysis using Atlas TI was conducted to develop themes relating to the impact 
on HRQL. The themes were organized into a conceptual model of the impact of LGS
on the HRQL of the parent and the child. RESULTS: Parents reported extensive dif-
ﬁ culties in every aspect of their own lives. Major themes included burden of care on 
work and social activities, stigma, frustration, anxiety and other physical issues
(including sleep disturbance), as well as concerns about the future for their child. With 
respect to the HRQL of the child, the parents reported that the physical functioning 
of the child is affected, particularly in relation to mobility difﬁ culties. LGS has a sig-
niﬁ cant affect on a child’s cognitive skills with some of the children not being able to 
talk. In addition, children with LGS tend to have little or no social skills and ﬁ nd
interacting with others difﬁ cult. CONCLUSIONS: LGS has a substantial negative 
effect on the HRQL of parents of a child with LGS as well as on the HRQL of the 
child him/herself.
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UTILITIES FOR MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A
SURVEY OF THE GENERAL PUBLIC IN CANADA
Tarride JE, Oremus M, Clayton N, Raina P
McMaster University, Hamilton, ON, Canada
OBJECTIVES: (1) To elicit health utility scores for moderate Alzheimer’s disease (AD)
using the Canadian general public; (2) to compare utility scores for Canadians’ 
self-assessed health status with utility scores for health status deﬁ ned as moderate AD;
(3) to measure awareness of AD; and (4) to determine factors that inﬂ uence utility
scores. METHODS: Five-hundred Canadians were chosen randomly to participate in 
a 13-minute telephone interview. The sample was national in scope and stratiﬁ ed by 
income. The EQ-5D was administered to measure utility for respondents’ current
health status (i.e., no AD). After describing moderate AD, respondents were asked to 
answer the EQ-5D again, this time imagining they had moderate AD. AD awareness
was measured with the Alzheimer’s Disease Knowledge Test (ADKT). Respondents
were also asked about socio-demographics and whether they knew someone with AD. 
OLS regressions were conducted to identify determinants of EQ-5D utility scores. 
RESULTS: The mean age of respondents was 51 years, 61% were female, and 42% 
knew someone with AD (e.g., family member). Mean ADKT score was 3.4 (SD: 1.1) 
out of 5 (higher scores indicate better knowledge of AD). Respondents’ mean EQ-5D 
score for their current health status was 0.857 (SD: 0.15). Mean EQ-5D score for a
hypothetical, moderate AD health status was 0.638 (SD: .20), a utility decrement of 
0.22. For the VAS component of the EQ-5D, scores were higher for the current health 
status (79.16 versus 57.66). Age and income were signiﬁ cant explanatory variables 
for current health status utilities, but only age was signiﬁ cant in the determination of 
the utility score under the assumption of moderate AD. Gender, knowledge of someone
with AD, or AD awareness scores had no impact. CONCLUSIONS: When measured 
by the EQ-5D, Canadians would expect to assign a lower utility to their health status 
when they have moderate AD.
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THE IMPACT OF DIFFERENT STAGES OF MULTIPLE SCLEROSIS ON
HEALTH UTILITIES: A SYSTEMATIC REVIEW OF THE LITERATURE
Naci H1, Fleurence R1, Birt J2, Duhig AM3
1United BioSource Corporation, Bethesda, MD, USA, 2Eli Lilly and Company, Indiana, IN, USA, 
3Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Multiple Sclerosis (MS) causes neurological disability of varying 
severity. Disability in MS is measured by the Kurtzke Expanded Disability Status
Scale (EDSS), a clinician-based neurological impairment rating scale (scale from 1 to 
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10, with 10 being death). For most patients, MS will progress from an episodic
disorder (relapsing-remitting MS) to a more progressive state (secondary progressive
MS). We conducted a systematic review of the literature to determine how health
related quality of life, as measured by health utilities, changes with the increasing
neurological disability associated with different stages of MS. METHODS: Employing
pre-deﬁ ned search terms and inclusion/exclusion criteria, systematic searches 
were conducted in MEDLINE, EMBASE, PsycINFO, Health Economic Evaluation 
Database (HEED), NHS Economic Evaluations Database (NHS/EED), and the UK 
National Institute for Health and Clinical Excellence (NICE) website. All databases
were searched from 1 January 1993 to 5 August 2008. Data extraction was validated 
by an independent reviewer. RESULTS: We identiﬁ ed 16 studies reporting health utili-
ties associated with health states of MS. EQ-5D was the most common preference
elicitation instrument. Health utilities ranged from 0.80 to 0.89 for patients with an
EDSS score of 1, from 0.49 to 0.71 for patients with an EDSS score of 3, from 0.39 
to 0.54 for patients with an EDSS score of 6.5, and from 0.19 to 0.08 for patients
with an EDSS score of 9 with some patients valuing their health states as worse than 
death. CONCLUSIONS: MS has a signiﬁ cant impact on quality of life. Utilities 
decrease signiﬁ cantly with increasing neurological disability. Without taking into 
consideration EDSS score, there appears to be no difference in health utilities between
RRMS and SPMS patients and the variation in health utilities appears to be mainly 
explained by the severity of the disability. Utilities also decreased signiﬁ cantly during 
relapse phases.
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THE USE OF ELECTRONIC PATIENT-REPORTED OUTCOMES WITHIN
CENTRAL NERVOUS SYSTEM PROTOCOLS
Wenzel K1, Logsdon M1, Meacham R2, Carrick L2
1Perceptive Informatics, Waltham, MA, USA, 2Perceptive Informatics, Nottingham, UK
OBJECTIVES: Central Nervous System (CNS) studies often incorporate the use of 
patient-reported outcomes (PROs) because of the nature of disorders being studied 
and their dependence on the subjective reports of study subjects1. To date, limited 
data has been published that sheds light on the types of instruments that are collected 
electronically (ePRO) in CNS trials. This research studied the breadth and depth of 
ePRO use through the analysis of a data set containing details of ePRO use in phase 
I-IV CNS drug trials. METHODS: A study of the characteristics of ePRO use in CNS
clinical drug trials was undertaken to understand the breath of CNS disorders areas
in which ePRO is being used as well as to understand how ePRO is being used within
these trials. A dataset of 91 clinical trials was analyzed by using ﬁ elds that describe
each protocol’s key elements including ePRO instrument, Phase, Assessment Fre-
quency, Disorder and Target Population. RESULTS: The analysis determined that 
Depression and sleep disorders respectively represented 33.3% and 34% of ePRO use 
for this dataset. Overall, ePRO was used in 12 different CNS disorders. ePRO was
most often used to collect primary efﬁ cacy data (24%), but other uses included second-
ary efﬁ cacy (22%) and safety (4.4%) data. The most common reporting frequency 
was for screening or study eligibility assessment (24%); this was followed closely by 
daily (19.8%) assessment. Of interest was that 79% of the time, a named instrument 
is used as opposed to a diary or symptom questionnaire (21%). CONCLUSIONS:
This research shows that PROs are not only being collected electronically, but that
ePRO use within CNS clinical trials is both broad and deep. Limitations of this study 
include the clinical trials of this dataset which can not be necessarily generalized as 
representative of all CNS ePRO use.
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CANADIAN PATIENT SURVEY TO ASSESS PATIENTS’ PLIGHT TO 
MOVEMENT DISORDER DIAGNOSES AND BOTULINUM TOXIN TYPE-A 
(BONTA) TREATMENT – FINAL RESULTS
Simonyi S1, Jog M2, The Canadian Movement Disorders Survey Group N3
1Allergan, Inc., Markham, ON, Canada, 2London Health Sciences Centre, London, ON, 
Canada, 3’, ‘, Canada
OBJECTIVES: To assess and describe the diagnostic and treatment pathways of move-
ment disorders responsive to BoNTA, Allergan Units and assess the types and number 
of health care professionals seen by patients before their movement disorder diagnosis 
was made and the length of time from onset of symptoms to diagnosis. METHODS:
Patients with movement disorders completed a 19-question survey developed by the
Canadian Movement Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset of symptoms, number and types of physicians 
seen, other diagnoses made, number of patients treated with BoNTA and distance 
traveled. RESULTS: In this ﬁ nal analysis, 879 patients with movement disorders 
responsive to BoNTA were surveyed. Majority of the patients were female (72%), 
traveling an average of 69 km one-way. Most common movement disorder diagnoses 
were cervical dystonia (42%), hemifacial spasm (20%), and blepharospasm (9%).
Common diagnoses made prior to the movement disorder diagnoses were nerve/muscle 
problem (33%), stress/psychological problem (39%), tremor (16%), ﬁ bromyalgia 
(14%), TMJ (10%), joint/tendon problem (15%) and spine (10%). The average 
number of physicians seen before the movement disorder diagnosis was 3.1. Amongst
these were family physicians (78%), neurologists (71%), movement disorder special-
ists (32%), chiropractors (17%), eye care doctors (17%), physiotherapists (17%), and
neurosurgeons (10%). Most physicians who made the current movement disorder
diagnoses were neurologists (63%) and movement disorder specialists (33%). The
average time in years from onset of symptoms to movement disorder diagnosis were:
cervical dystonia 6.6, blepharospasm 4.7, hemifacial spasm 3.8, spasmodic dysphonia 
2.5, limb dystonia 8.2, Meige syndrome 2.8, generalized dystonia 1.6, oromandibular 
dystonia 2.1. 95% of patients were treated with BoNTA following their movement
disorder diagnosis. CONCLUSIONS: The number of physicians seen and length of 
time from onset to movement disorder diagnoses are considerable. Increased aware-
ness of movement disorders at the primary care level may improve these rates.
PND30
DATA ANALYSIS OF PEDIATRIC INPATIENTS DIAGNOSED WITH
BRAIN ABSCESS
Redd R
University of Louisville, Louisville, KY, USA
OBJECTIVES: Brain abscess is a somewhat rare condition found more commonly in 
pediatric patients than young adults. While fatalities as a result of brain abscesses have 
decreased signiﬁ cantly in recent years, the possibility of the condition being fatal is 
very real. Early diagnosis and treatment are the keys to effectively resolving the issue. 
The purpose of this paper is to examine patient outcomes for those diagnosed with
brain abscess. METHODS: Data were taken from the National Inpatient Sample
(NIS). The data consist of pediatric patients diagnosed with brain abscesses (N  252) 
and a randomly selected control group (N  260). SAS Enterprise Guide, a statistical
software program, was used to analyze the data set and provide an overview of the
results. Methods used included one-way frequencies, statistical summaries, kernel
density estimations, and linear and logistic regression models. RESULTS: Contrary to 
other sources, the age of pediatric patients in the sample seems to play a role in the
likelihood of developing brain abscesses. Factors such as age, gender, and race were 
shown by several different methods to be not signiﬁ cant in the diagnosis. The mortality 
rate was found to be ﬁ ve times higher in the treatment group than the control sug-
gesting that while this condition may be declining with respect to deaths, the rate is 
still signiﬁ cantly higher than a random control group from the NIS database. CON-
CLUSIONS: While the mortality rate for brain abscesses is low, current procedures 
can still be improved to lower the rate further. New techniques of diagnosing brain
abscesses can also be developed with the research found in the NIS. Further studies 
should be performed in order to ﬁ nd more relationships. Finding the connection 
between these connections may lead to better preventive measures and improved
treatments for brain abscesses.
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FACTORS ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE
IN MULTIPLE SCLEROSIS PATIENTS RECEIVING NATALIZUMAB
Agarwal S1, Stephenson JJ2, Rajagopalan K3, Kamat S2
1Biogen Idec Pharmaceuticals, Wellesley, MA, USA, 2HealthCore, Inc., Wilmington, DE, USA, 
3Biogen Idec Pharmaceuticals, Cambridge, MA, USA
OBJECTIVES: To assess factors associated with health-related quality of life (HRQoL) 
in MS patients after three natalizumab infusions. METHODS: MS patients, newly 
enrolled in the manufacturer’s restricted drug distribution program and participating
in a longitudinal study of their experiences with natalizumab, complete assessments
prior to treatment initiation and after the 3rd, 6th and 12th infusion. HRQoL was 
assessed with the SF-12v2 where higher physical and mental component summary 
(PCS and MCS) scores indicated improvement in HRQoL. Univariate, followed by 
multivariate, linear regression was used to identify factors associated with HRQoL
after three natalizumab infusions. The factors used in this analysis include age, clinical 
characteristics (disease duration, number of prior MS treatments) and baseline (BL) 
disease severity measures (disease step (DS), functional status, fatigue score, cognitive 
functioning (CF) score). RESULTS: At the time of this analysis 504 patients had 
completed BL and 3rd assessments. Mean age was 46.08 o 10.93, 78% of patients 
were female, and mean disease duration was 9.64 o 8.33 years. PCS and MCS scores
improved signiﬁ cantly from baseline (PCS: 34.03 versus 36.02; p  0.001) and MCS:
43.17 versus 47.22; p  0.001). Multivariate analysis indicated that higher BL PCS
scores (p  0.001), lower BL DS scores (p  0.001) and younger age (p  0.002) were 
associated with improvement in PCS scores after three natalizumab infusions. Simi-
larly, higher BL MCS (p  0.001) and BL CF scores (p  0.001) were associated with 
improvement in MCS scores after the 3rd infusion. CONCLUSIONS: Factors associ-
ated with improvement in PCS scores after the 3rd infusion were younger age, higher 
BL PCS scores, and lower BL DS scores (better ambulation) while those associated
with improvements in MCS scores were higher BL MCS scores and higher BL CF 
scores. These results suggest that initiating natalizumab in younger patients having 
lower disability and better baseline HRQoL results in greater improvements in 
HRQoL after three natalizumab infusions.
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PREDICTORS OF PATIENT- AND PHYSICIAN-REPORTED SATISFACTION/
EASE-OF-USE RATINGS WITH RASAGILINE IN PARKINSON’S DISEASE
Buck PO, Castelli-Haley J, Conner JB
Teva Neuroscience, Kansas City, MO, USA
OBJECTIVES: Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
that affects 1 million people in the United States. Several available treatments are 
effective in controlling its symptoms; however, relatively little research has examined
patient- and physician-reported PD treatment satisfaction/ease-of-use (SEU) ratings.
These post-hoc analyses examined whether improvement in PD symptoms and dis-
abilities predicted subsequent ratings of SEU with rasagiline, a selective irreversible 
monoamine oxidase type-B inhibitor. METHODS: The LEGATO trial was an open-
label study of 0.5 mg and 1.0 mg once daily rasagiline in PD patients at 38 commu-
nity-based centers in the United States. Baseline treatment determined patients’
